BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38604299)

  • 1. Discovery of novel nucleoside derivatives as selective lysine acetyltransferase p300 inhibitors for cancer therapy.
    Dai Q; Yuan Z; Sun Q; Ao Z; He B; Jiang Y
    Bioorg Med Chem Lett; 2024 May; 104():129742. PubMed ID: 38604299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
    Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
    Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein lysine acetyltransferase CBP/p300: A promising target for small molecules in cancer treatment.
    Gou P; Zhang W
    Biomed Pharmacother; 2024 Feb; 171():116130. PubMed ID: 38215693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
    Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
    J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP.
    Nie S; Wu F; Wu J; Li X; Zhou C; Yao Y; Song Y
    Eur J Med Chem; 2022 Jul; 237():114407. PubMed ID: 35512565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
    Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
    Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents.
    Chen Q; Yang B; Liu X; Zhang XD; Zhang L; Liu T
    Theranostics; 2022; 12(11):4935-4948. PubMed ID: 35836809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors.
    Yang Y; Zhang R; Li Z; Mei L; Wan S; Ding H; Chen Z; Xing J; Feng H; Han J; Jiang H; Zheng M; Luo C; Zhou B
    J Med Chem; 2020 Feb; 63(3):1337-1360. PubMed ID: 31910017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.
    Lu W; Xiong H; Chen Y; Wang C; Zhang H; Xu P; Han J; Xiao S; Ding H; Chen Z; Lu T; Wang J; Zhang Y; Yue L; Liu YC; Zhang C; Yang Y; Jiang H; Chen K; Zhou B; Luo C
    Bioorg Med Chem; 2018 Nov; 26(20):5397-5407. PubMed ID: 30297119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of anticancer activity of CBP/p300 inhibitors - Features of their classes, intracellular targets and future perspectives of their application in cancer treatment.
    Strachowska M; Robaszkiewicz A
    Pharmacol Ther; 2024 May; 257():108636. PubMed ID: 38521246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of berberine analogs as potent and highly selective p300/CBP HAT inhibitors.
    Zhong X; Deng H; Long M; Yin H; Zhong Q; Zheng S; Gong T; He L; Wang G; Sun Q
    Bioorg Chem; 2023 Sep; 138():106597. PubMed ID: 37245245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current development of CBP/p300 inhibitors in the last decade.
    He ZX; Wei BF; Zhang X; Gong YP; Ma LY; Zhao W
    Eur J Med Chem; 2021 Jan; 209():112861. PubMed ID: 33045661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents.
    Yang H; Pinello CE; Luo J; Li D; Wang Y; Zhao LY; Jahn SC; Saldanha SA; Chase P; Planck J; Geary KR; Ma H; Law BK; Roush WR; Hodder P; Liao D
    Mol Cancer Ther; 2013 May; 12(5):610-20. PubMed ID: 23625935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells.
    Gu ML; Wang YM; Zhou XX; Yao HP; Zheng S; Xiang Z; Ji F
    Oncol Rep; 2016 Nov; 36(5):2763-2770. PubMed ID: 27633918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors.
    Liu R; Zhang Z; Yang H; Zhou K; Geng M; Zhou W; Zhang M; Huang X; Li Y
    Eur J Med Chem; 2019 Oct; 180():171-190. PubMed ID: 31306905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors.
    Popp TA; Tallant C; Rogers C; Fedorov O; Brennan PE; Müller S; Knapp S; Bracher F
    J Med Chem; 2016 Oct; 59(19):8889-8912. PubMed ID: 27673482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.
    Bowers EM; Yan G; Mukherjee C; Orry A; Wang L; Holbert MA; Crump NT; Hazzalin CA; Liszczak G; Yuan H; Larocca C; Saldanha SA; Abagyan R; Sun Y; Meyers DJ; Marmorstein R; Mahadevan LC; Alani RM; Cole PA
    Chem Biol; 2010 May; 17(5):471-82. PubMed ID: 20534345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel berberine derivatives as p300 histone acetyltransferase inhibitors in combination treatment for breast cancer.
    Lai R; Lin Z; Yang C; Hai L; Yang Z; Guo L; Nie R; Wu Y
    Eur J Med Chem; 2024 Feb; 266():116116. PubMed ID: 38215590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases.
    Mai A; Rotili D; Tarantino D; Nebbioso A; Castellano S; Sbardella G; Tini M; Altucci L
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1132-5. PubMed ID: 19144517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting p300/CBP Attenuates Hepatocellular Carcinoma Progression through Epigenetic Regulation of Metabolism.
    Cai LY; Chen SJ; Xiao SH; Sun QJ; Ding CH; Zheng BN; Zhu XY; Liu SQ; Yang F; Yang YX; Zhou B; Luo C; Zhang X; Xie WF
    Cancer Res; 2021 Feb; 81(4):860-872. PubMed ID: 33361394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.